Edition:
India

Sun Pharma Advanced Research Company Ltd (SPRC.NS)

SPRC.NS on National Stock Exchange of India

365.25INR
19 Oct 2017
Change (% chg)

Rs1.45 (+0.40%)
Prev Close
Rs363.80
Open
Rs366.60
Day's High
Rs369.00
Day's Low
Rs341.95
Volume
61,741
Avg. Vol
544,810
52-wk High
Rs431.00
52-wk Low
Rs272.00

Chart for

About

Sun Pharma Advanced Research Company Limited is engaged in the research and experimental development on natural sciences and engineering (Pharmacy). The Company operates through Pharmaceuticals Research & Development segment. Its programs include Xelpros, Elepsia XR, Baclofen GRS, Paclitaxel Injection Concentrate for Nanodispers... (more)
No analyst recommendations are available for .

Overall

Beta: 1.30
Market Cap(Mil.): Rs96,005.50
Shares Outstanding(Mil.): 246.90
Dividend: --
Yield (%): --

Financials

BRIEF-Sun Pharma Advanced Research Co announces top-line results of action study for Baclofen GRS

* Announces top-line results of phase III efficacy study & duration of action study for Baclofen GRS

06 Oct 2017

TABLE-India's Sun Pharma Advanced Research June qtr loss widens

Aug 5 Three months ended June 30 versus the same period a year earlier (in million rupees) June 2017 June 2016 Net loss 788.4 361.4 Total Income 246.2 245.0 Note: Sun Pharma Advanced Research Company Ltd is a pharmaceuticals research and development company. (Reporting by Malini Menon in NEW DELHI; Editing by Paul Tait)

05 Aug 2017

BRIEF-Sun Pharma Advanced Research Co seeks members' nod to approve transactions with Sun Pharmaceutical Industries Inc

* Seeks members' nod to approve transactions with Sun Pharmaceutical Industries Inc, USA

10 Jul 2017

BRIEF-India's Sun Pharma Advanced Research March-qtr loss widens

* Net loss in March quarter last year was 95.8 million rupees as per Ind-As; total revenue was 434.9 million rupees Source text: http://bit.ly/2q6aPWX Further company coverage:

05 May 2017

BRIEF-Sun Pharma Advanced Research to consider raising of additional funds

* Says to consider a proposal for raising of additional funds Source text for Eikon: Further company coverage:

02 May 2017

Earnings vs. Estimates